When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Side effects may include bleeding, most commonly from the nose, gastrointestinal tract (GI) or genitourinary system. [2] Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2]

3. Rivaroxaban - Wikipedia

   en.wikipedia.org/wiki/Rivaroxaban

   Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. [8] Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. [ 8 ]

4. Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 ...

   www.aol.com/news/bayer-j-j-settle-thousands...

   Lawsuits over Xarelto began piling up in 2014 and the companies had so far won all six trials over Xarelto's alleged bleeding risk. Bayer, J&J settle thousands of U.S. Xarelto lawsuits for $775 ...

5. Xarelto Makers Created 'False Narrative' in Phila. Trial ...

   www.aol.com/news/xarelto-makers-created-apos...

   For premium support please call: 800-290-4726 more ways to reach us

6. List of SJS-inducing substances - Wikipedia

   en.wikipedia.org/wiki/List_of_SJS-inducing...

   Xarelto: Sitagliptin [citation needed] Sulfonamides [2] Tetracycline [2 This page was last edited on 6 August 2024, at 09:55 (UTC). Text is available ...

7. Xarelto Plaintiffs Push Back Against Pre-emption Defense on ...

   www.aol.com/news/xarelto-plaintiffs-push-back...

   Plaintiffs, appealing three defense verdicts, responded on Friday to a cross-appeal that sought to toss 20,000 cases over Xarelto on federal pre-emption.

8. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]

9. Bayer's patent for blood thinner Xarelto invalid, UK ... - AOL

   www.aol.com/news/bayers-patent-blood-thinner...

   Bayer's patent covering its best-selling blood thinner Xarelto is invalid, London's High Court ruled on Friday in a blow to the German drugmaker. The company's blockbuster Xarelto drug generated ...